|
× |
 |
Cost-Effectiveness of 12-Month Therapeutic Assertive Community Treatment as Part of Integrated Care Versus Standard Care in Patients With Schizophrenia Treated With Quetiapine Immediate Release (ACCESS Trial) PDF |
$40.00 |
|
$40.00 |
|
× |
|
Ziprasidone in Treatment-Resistant Schizophrenia: A 52-Week, Open-Label Continuation Study PDF |
$40.00 |
|
$40.00 |
|
× |
|
Psychiatric Care of the Patient With Hepatitis C: A Review of the Literature PDF |
$40.00 |
|
$40.00 |
|
× |
|
Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression PDF |
$40.00 |
|
$40.00 |
|
× |
|
A Preliminary, Randomized Trial of Fluoxetine, Olanzapine, and the Olanzapine-Fluoxetine Combination in Women With Borderline Personality Disorder PDF |
$40.00 |
|
$40.00 |
|
× |
|
"Extended" Antipsychotic Dosing in the Maintenance Treatment of Schizophrenia: A Double-Blind, Placebo-Controlled Trial PDF |
$40.00 |
|
$40.00 |
|
× |
|
Trends in Medication Prescribing in Patients With PTSD From 2009 to 2018: A National Veterans Administration Study PDF |
$40.00 |
|
$40.00 |
|
× |
|
Mood Symptoms, Functional Impairment, and Disability in People With Bipolar Disorder: Specific Effects of Mania and Depression. PDF |
$40.00 |
|
$40.00 |
|
× |
|
Nefazodone in the Treatment of Generalized Social Phobia: A Randomized, Placebo-Controlled Trial PDF |
$40.00 |
|
$40.00 |
|
|
